Kelleher
Anthony Dominic Kelleher, Bangor AU
Patent application number | Description | Published |
---|---|---|
20110229448 | METHOD FOR IDENTIFYING ANTIGEN-SPECIFIC REGULATORY T CELLS - A method of identifying an antigen-specific regulatory T cell (Treg) from a subject is discussed wherein the method comprises quantitatively or qualitatively detecting co-expression of each of cell markers CD4, CD25 and CD134, or alternatively, N each of cell markers CD8, CD25 and CD137, as well as one or more cell markers selected from the group of Treg cell markers consisting of CD39, CD73, CD127, CTLA-4 and Foxp3 on a cell in a suitable lymphocyte-containing sample from the subject in response to exposure to a target antigen. Also discussed are methods of isolating and expanding the identified antigen-specific Treg population, which may permit antigen-specific Treg cell therapy. | 09-22-2011 |
20110318749 | METHOD FOR IDENTIFYING REGULATORY T CELLS - The present invention relates to methods and kits for identifying, quantifying and isolating regulatory T cells, to methods and kits for diagnosing or monitoring autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer, cancer treatment and/or organ transplantation based on regulatory T cell quantity, to methods and kits for predicting responses to therapy for autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer and/or organ transplantation based on regulatory T cell quantity, and to methods and kits for therapy using isolated regulatory T cells. | 12-29-2011 |
Anthony Dominic Kelleher, Bangor Nsw AU
Patent application number | Description | Published |
---|---|---|
20120225083 | VIRAL POLYPEPTIDES AND METHODS - The invention is directed to polypeptides and polypeptide fragments from HIV-1 envelope (Env) proteins following the characterization of Env structures from environments where HIV isolates expose conserved neutralization-sensitive Env structures. There is provided a polypeptide being all or a fragment of an HIV-1 envelope protein from a transmission strain of HIV-1, the polypeptide having neutralization sensitive epitopes that are accessible. | 09-06-2012 |
Anthony Dominic Kelleher, New South Wales AU
Patent application number | Description | Published |
---|---|---|
20090221005 | METHOD FOR DETECTING ANTIGEN SPECIFIC OR MITOGEN-ACTIVATED T CELLS - The present invention comprises a method for the quantitative or qualitative detection of antigen-specific CD4+ T cells and/or CD8+ T cells in a subject, said method comprising quantitatively or qualitatively detecting the expression of cell surface marker CD25 and one or more of cell surface markers CD134 and CD137 in a suitable lymphocyte-containing sample from said subject in response to exposure to an antigen. A method for determining the immunocompetence of a subject and a method for isolating antigen-specific CD4+ and/or CD8+ T cells is also disclosed. | 09-03-2009 |
20100028865 | Method for Identifying Regulatory T Cells - The present invention relates to methods and kits for identifying, quantifying and isolating regulatory T cells, to methods and kits for diagnosing or monitoring autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer, cancer treatment and/or organ transplantation based on regulatory T cell quantity, to methods and kits for predicting responses to therapy for autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer and/or organ transplantation based on regulatory T cell quantity, and to methods and kits for therapy using isolated regulatory T cells. | 02-04-2010 |
Christopher Charles Kelleher, Hampshire GB
Patent application number | Description | Published |
---|---|---|
20110031354 | Aircraft - An aircraft, particularly a solar powered, high altitude, long endurance, unmanned aerial vehicle, is equipped with a combination of canted down, raked back wing tips and trailing “tip tails” carried on booms from the tip regions of the mainplane. Each tip tail is positioned to be subject to the upwash field of the respective wing tip vortex, at least in the cruise condition of the aircraft. The wing tip form can achieve a reduction in induced drag and help to relieve wing root bending moment while the tip tails can act through their connections to the mainplane to provide torsional relief to the latter, particularly under lower incidence/higher speed conditions. In the higher incidence/lower speed cruise condition, however, the presence of the tip tails in the upwash fields of the wing tip vortices means that they can generate lift with a component in the forward direction of flight and hence contribute to the thrust requirements of the aircraft. | 02-10-2011 |
Dermot Kelleher, Dun Laoghaire IE
Patent application number | Description | Published |
---|---|---|
20120129176 | CYTOKINES AS PROGNOSTIC MARKERS OF RESPIRATORY-TRACT INFECTION FOLLOWING MAJOR SURGERY - The invention relates to the use of a certain subset of cytokine markers as prognostic variables of infection status in an individual, and especially as prognostic markers of a patients developing severe infection such as pneumonia, and respiratory tract infection following surgery. The subset of cytokine markers consists of the interleukin cytokines IL-2, IL-7, IL-23, IL-27, and IL-IO, and Interferon-γ (INFγ) and Tissue Necrosis Factor-α (TNFα). The markers may be employed as individual prognostic variables of infection status, or they may be used in pairs or other combinations. Generally, the abundance of the markers is correlated with infection status by means of an absolute pre-operative value of biomarker abundance, ratio's of pre-operative to post-operative biomarker abundance, or ratio values for pairs of certain biomarkers within the subset. Typically, cytokine abundance is expressed in terms of mRNA copy number wherein the copy numbers are ideally normalised to a house keeping gene and quantification of mRNA copy number is determined by RT-PCR containing reference serial dilutions of cytokine specific cDNA. | 05-24-2012 |
20120149785 | METHOD OF ESTIMATING SEPSIS RISK IN AN INDIVIDUAL WITH INFECTION - A method of estimating sepsis risk in an individual with infection comprises a step of assaying a biological sample from the individual for an IL-2 or IL-7 mRNA value, and correlating the mRNA value with sepsis risk. The IL-2 and IL-7 mRNA values are quantified by absolute quantification of mRNA copy number, wherein the copy numbers are normalised to a house keeping gene and corrected against a calibration curve for serial dilutions of the IL-2 and IL-7 cDNA. The method generally involves a step of assaying a biological sample from the individual for IL-2 and/or IL-7 mRNA values, optionally in combination with mRNA values for other cytokines, and correlating a sum or difference of the values with sepsis risk using a regression analysis curve against outcome. | 06-14-2012 |
20150197808 | CYTOKINES AS PROGNOSTIC MARKERS OF RESPIRATORY-TRACT INFECTION FOLLOWING MAJOR SURGERY - The invention relates to the use of a certain subset of cytokine markers as prognostic variables of infection status in an individual, and especially as prognostic markers of a patients developing severe infection such as pneumonia, and respiratory tract infection following surgery. The subset of cytokine markers consists of the interleukin cytokines IL-2, IL-7, IL-23, IL-27, and IL-10, and Interferon-γ (INFγ) and Tissue Necrosis Factor-α (TNFα). The markers may be employed as individual prognostic variables of infection status, or they may be used in pairs or other combinations. Generally, the abundance of the markers is correlated with infection status by means of an absolute pre-operative value of biomarker abundance, ratio's of pre-operative to post-operative biomarker abundance, or ratio values for pairs of certain biomarkers within the subset. Typically, cytokine abundance is expressed in terms of mRNA copy number wherein the copy numbers are ideally normalised to a house keeping gene and quantification of mRNA copy number is determined by RT-PCR containing reference serial dilutions of cytokine specific cDNA. | 07-16-2015 |
Dermot Kelleher, Country Dublin IE
Patent application number | Description | Published |
---|---|---|
20090297474 | Method for Detecting or Monitoring Sepsis by Analysing Cytokine mRNA Expression Levels - The present invention relates to a method for identifying patients who are likely to develop sepsis in response to infection, a method for monitoring the progress of sepsis in a patient and to an assay kit for identifying patients who are likely to develop sepsis and/or monitoring the progress of sepsis. | 12-03-2009 |
Dermot Kelleher, Co. Dublin IE
Patent application number | Description | Published |
---|---|---|
20140051073 | METHOD OF ESTIMATING RISK OF SEVERE SEPSIS IN AN INDIVIDUAL WITH INFECTION - A method of estimating sepsis risk in an individual with infection comprises a step of assaying a biological sample from the individual for an IL-2 or IL-7 mRNA value, and correlating the mRNA value with sepsis risk. The IL-2 and IL-7 mRNA values are quantified by absolute quantification of mRNA copy number, wherein the copy numbers are normalised to a house keeping gene and corrected against a calibration curve for serial dilutions of the IL-2 and IL-7 cDNA. The method generally involves a step of assaying a biological sample from the individual for IL-2 and/or IL-7 mRNA values, optionally in combination with mRNA values for other cytokines, and correlating a sum or difference of the values with sepsis risk. | 02-20-2014 |
Dermot Kelleher, Dublin IE
Patent application number | Description | Published |
---|---|---|
20090082314 | Targeting Prodrugs for the Treatment of Gastrointestinal Diseases - Provided herein are compounds, compositions and methods for decreasing NFκB DNA-binding activity in a patient comprising administering of a therapeutically effective amount of a compound or composition of the application to the patient to reduce, alleviate or treat various gastrointestinal diseases, such as inflammatory bowel disease (IBD). | 03-26-2009 |
20120094963 | TARGETING PRODRUGS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES - Provided herein are compounds of formula (I) as well as compounds of formula (I) which are prodrugs in which the (R7)a-phenyl-S(O)2NH group represents a sulphonamide-bond compound, compositions and methods for preventing or treating gastrointestinal diseases such as inflammatory bowel disease and colorectal cancer, wherein the method comprises delivering an effective amount of a COX-2 or a similar sulphonamide inhibitor as a prodrug or a derivative thereof to the colon, wherein the COX-2 or similar inhibitor is released in vivo. | 04-19-2012 |
Dermot Kelleher, County Dublin IE
Patent application number | Description | Published |
---|---|---|
20090197291 | Assays Using Nanoparticles - A method for quantitatively and qualitatively determining the presence of a macromolecule comprises providing nanoparticles in a buffered solution, adding a test sample to the buffered nanoparticle solution, and measuring the difference between the buffered nanoparticles in the presence and absence of the test sample. The nanoparticles are preferably less than 100 nm in size. | 08-06-2009 |
20100197525 | SUBSTANCE AND A DEVICE | 08-05-2010 |
20110172128 | MULTI-WELL DEVICE - A device comprising a plurality of sample wells wherein the device has a plurality of compartments, each compartment surrounding at least one well. The compartments are defined by compartment wall means. The compartment wall means may be associated with at least one well or the compartment wall means may be associated with a group of wells. The compartment may house an environmental buffering system. | 07-14-2011 |
20130040299 | METHOD FOR DETECTING OR MONITORING SEPSIS BY ANALYSING CYTOKINE MRNA EXPRESSION LEVELS - The present invention relates to a method for identifying patients who are likely to develop sepsis in response to infection, a method for monitoring the progress of sepsis in a patient and to an assay kit for identifying patients who are likely to develop sepsis and/or monitoring the progress of sepsis. | 02-14-2013 |
Joanne Kelleher, Dublin IE
Patent application number | Description | Published |
---|---|---|
20130267561 | Substituted 1,3-Dioxanes Useful as PPAR Modulators - Specifically useful stereoisomers of 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections as well as their use in the treatment of a disease related to TP, such as cardiovascular diseases. | 10-10-2013 |
Liam Kelleher, Galway IE
Patent application number | Description | Published |
---|---|---|
20150268885 | INPUT/OUTPUT OPERATIONS AT A VIRTUAL BLOCK DEVICE OF A STORAGE SERVER - Example embodiments disclosed herein relate to input/output (I/O) operations at a virtual block device of a storage server. Example embodiments include requesting an input/output (I/O) operation at an offset of a virtual block device of a storage server in response to a virtual machine request for an I/O operation at a virtual disk. | 09-24-2015 |
Liam Noel Kelleher, Oranmore IE
Patent application number | Description | Published |
---|---|---|
20130198738 | INPUT/OUTPUT OPERATIONS AT A VIRTUAL BLOCK DEVICE OF A STORAGE SERVER - Example embodiments disclosed herein relate to input/output (I/O) operations at a virtual block device of a storage server. Example embodiments include requesting an input/output (I/O) operation at an offset of a virtual block device of a storage server in response to a virtual machine request for an I/O operation at a virtual disk. | 08-01-2013 |
20130227552 | PERSISTENT VOLUME AT AN OFFSET OF A VIRTUAL BLOCK DEVICE OF A STORAGE SERVER - Example embodiments disclosed herein relate to a persistent volume at an offset of a virtual block device of a storage server. Example embodiments include requesting that a persistent volume be dissociated from a virtual block device in response to the termination of a virtual machine. | 08-29-2013 |
Mark Kelleher, Aitkenvale AU
Patent application number | Description | Published |
---|---|---|
20110031039 | WEIGHING APPARATUS - A weighing apparatus, the weighing apparatus comprising a weighing portion including means for at least temporarily retaining an item to be weighed thereon, and a measurement portion in communication with the weighing portion, wherein the measurement portion comprises at least two indicators for indicating the weight of the item attached to the weighing apparatus, each of the indicators for indicating the weight of the item in different conditions. | 02-10-2011 |
Michael Kelleher, Mt. Pelerin CH
Michelle Kelleher, Oxford GB
Patent application number | Description | Published |
---|---|---|
20090047307 | Chemo-Immunotherapy Method - A method of treating or preventing disease, said method comprising administering to a subject, simultaneously, sequentially or separately, an antigen and a chemotherapeutic agent or agents comprising the steps of: administering the chemotherapeutic agent or agents, and administering an antigen up to 6 weeks after the chemotherapeutic agent. | 02-19-2009 |
Michelle Kelleher, Wantage GB
Patent application number | Description | Published |
---|---|---|
20100166652 | Laminin receptor 1 precursor protein (37LRP) epitope delineated by an hepatocellular carcinoma specific antibody - This invention relates to the diagnosis and treatment of cancerous diseases, particularly to such diagnosis and treatment which revolves around the ability of the 5LAC-23 monoclonal antibody (or antigenic binding fragments derived therefrom) to bind with the Laminin Receptor 1 Precursor Protein 37LRP; and most particularly to diagnosis and treatment of Hepatocellular Carcinoma by various means which rely upon direct binding of 5LAC-23 with the particular antigenic moiety specifically recognized thereby and generally overexpressed in Hepatocellular carcinoma cells. The invention additionally relates to the treatment of such cells with conjugated moieties effective to aid in differentiation, treatment and diagnostic imaging thereof. | 07-01-2010 |
Michelle Kelleher, Oxfordshire GB
Patent application number | Description | Published |
---|---|---|
20120213822 | CHEMO-IMMUNOTHERAPY METHOD - A method of treating or preventing disease, said method comprising administering to a subject, simultaneously, sequentially or separately, an antigen and a chemotherapeutic agent or agents comprising the steps of: administering the chemotherapeutic agent or agents, and administering an antigen up to 6 weeks after the chemotherapeutic agent. | 08-23-2012 |
Patrick Kelleher, Ringaskiddy IE
Patent application number | Description | Published |
---|---|---|
20090042262 | Preparation of Pregabalin and Related Compounds - Materials and Methods for preparing (S)-(+)-3-aminomethyl-5-methyl-hexanoic acid and structurally related compounds via enzymatic kinetic resolution are disclosed. | 02-12-2009 |
20110065168 | Preparation of Pregabalin and Related Compounds - Materials and methods for preparing (S)-(+)-3-aminomethyl-5-methyl-hexanoic acid and structurally related compounds via enzymatic kinetic resolution are disclosed. | 03-17-2011 |
20120015412 | Preparation of Pregabalin and Related Compounds - Materials and methods for preparing (S)-(+)-3-aminomethyl-5-methyl-hexanoic acid and structurally related compounds via enzymatic kinetic resolution are disclosed. | 01-19-2012 |